Macrogenics (MGNX) Non-Current Assets (2012 - 2026)
Macrogenics (MGNX) posted quarterly Non-Current Assets of $35.4 million for Q1 2026, down 16.78% year-over-year from $42.5 million in Q1 2025, and down 4.21% quarter-over-quarter from $36.9 million in Q4 2025.
Macrogenics (MGNX) Non-Current Assets (2012 - 2026) Analysis & Trends
Macrogenics (MGNX) has reported Non-Current Assets for 15 consecutive years, with $35.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets fell 16.78% year-over-year to $35.4 million; the TTM figure through Mar 2026 stood at $151.4 million (down 12.55% YoY), while the FY2025 annual figure was $36.9 million, down 16.44% from the prior year.
- Non-Current Assets declined to $35.4 million in Q1 2026 per MGNX's latest filing, from $36.9 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $58.3 million in Q4 2022 and bottomed at $35.4 million in Q1 2026.
- Historically, Non-Current Assets has averaged $45.9 million across 5 years, with a median of $45.7 million in 2024.
- Annual changes were most pronounced in 2022 — Non-Current Assets advanced 4.67% — and 2023, when it fell 19.23%.
- Macrogenics' Non-Current Assets stood at $58.3 million in 2022, then dropped by 19.23% to $47.1 million in 2023, then decreased by 6.19% to $44.2 million in 2024, then slipped by 16.44% to $36.9 million in 2025, then slipped by 4.21% to $35.4 million in 2026.
- Business Quant data shows MGNX's Non-Current Assets at $35.4 million in Q1 2026, $36.9 million in Q4 2025, and $38.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Macrogenics | 268.22 Mn | 201.71 Mn | - | 35.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 35.35 Mn |
| Dec 31, 2025 | 36.91 Mn |
| Sep 30, 2025 | 38.67 Mn |
| Jun 30, 2025 | 40.47 Mn |
| Mar 31, 2025 | 42.48 Mn |
| Dec 31, 2024 | 44.17 Mn |
| Sep 30, 2024 | 42.30 Mn |
| Jun 30, 2024 | 44.19 Mn |
| Mar 31, 2024 | 45.71 Mn |
| Dec 31, 2023 | 47.08 Mn |
| Sep 30, 2023 | 48.65 Mn |
| Jun 30, 2023 | 50.98 Mn |
| Mar 31, 2023 | 54.56 Mn |
| Dec 31, 2022 | 58.29 Mn |
| Sep 30, 2022 | 47.54 Mn |
| Jun 30, 2022 | 50.41 Mn |
| Mar 31, 2022 | 53.24 Mn |
| Dec 31, 2021 | 55.69 Mn |
| Sep 30, 2021 | 57.46 Mn |
| Jun 30, 2021 | 58.92 Mn |